Ken Fisher’s Syndax Pharmaceuticals SNDX Stock Holding History

Ken Fisher’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-147	Closed	-$3.1K	–	1202
2023 Q1	$3.1K	Buy	+147	New	+$3.66K	﹤0.01%	1086

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ken Fisher's SNDX Position: Q2 2023 in Review

Ken Fisher sold out of Syndax Pharmaceuticals (SNDX) in Q2 2023, closing a stake of 147 shares — an estimated $3.1K sold.

Ken Fisher first reported a position in SNDX in Q1 2023 and held it in 1 quarter. The position peaked at $3.1K in Q1 2023. 166 funds tracked by Wall St. Rank hold SNDX as of Q2 2023.

Ken Fisher reported no remaining Syndax Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ken Fisher sold 147 Syndax Pharmaceuticals shares in Q2 2023, an estimated $3.1K.
Ken Fisher first reported a position in Syndax Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Ken Fisher's Syndax Pharmaceuticals position peaked at $3.1K in Q1 2023.
166 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2023.

Based on Fisher Asset Management's 13F filing for Q2 2023, filed 8 Aug 2023.